Axogen grows 26% in Q3 2026, expanding nerve repair market with $200M BioCircuit buy

Axogen reported 26% revenue growth and 45% adjusted EBITDA growth in Q3 2026, driven by its evolving role as a key platform in peripheral nerve repair. The company’s $200 million acquisition of BioCircuit (NerveTape) removes technical barriers for surgeons and broadens its market reach. Axogen expects at least $290 million in sales for 2026 with a gross margin above 73%, benefiting from strong clinical evidence, payer coverage, and a large underpenetrated $5.6 billion U.S. nerve care market. This positions Axogen as a leading player with a premium valuation supported by its unique market position and growth prospects.

As of Oct 30, 2026 23:41 WIB, Axogen (AXGN) shares are trading at USD 48.95 on Pluang, down 1.38% for the day. The stock has a market cap of $2.96 billion and an enterprise value of $2.63 billion. Pluang investors show balanced interest with a 50% sell and 50% buy order split, reflecting steady engagement in this health sector stock.